And Hydrogen Iodide
Total Page:16
File Type:pdf, Size:1020Kb
1 NAC/Interim 2: 04/2010 2 3 4 5 6 INTERIM 7 ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) 8 FOR 9 HYDROGEN BROMIDE (CAS Reg. No. 10035-10-6) 10 AND 11 HYDROGEN IODIDE (CAS Reg. No. 10034-85-2) 12 13 HBr and HI 14 HYDROGEN BROMIDE/HYDROGEN IODIDE NAC/Interim 2: 04/2010 Page 2 of 34 1 PREFACE 2 3 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 4 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous 5 Substances (NAC/AEGL Committee) has been established to identify, review and interpret 6 relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic 7 chemicals. 8 9 AEGLs represent threshold exposure limits for the general public and are applicable to 10emergency exposure periods ranging from 10 minutes to 8 hours. Three levels C AEGL- 111, AEGL-2 and AEGL-3 C are developed for each of five exposure periods (10 and 30 12 minutes, 1 hour, 4 hours, and 8 hours) and are distinguished by varying degrees of 13 severity of toxic effects. The three AEGLs are defined as follows: 14 15AEGL-1 is the airborne concentration (expressed as parts per million or milligrams per 16cubic meter [ppm or mg/m3]) of a substance above which it is predicted that the general 17 population, including susceptible individuals, could experience notable discomfort, 18 irritation, or certain asymptomatic, non-sensory effects. However, the effects are not 19 disabling and are transient and reversible upon cessation of exposure. 20 21AEGL-2 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 22 which it is predicted that the general population, including susceptible individuals, could 23 experience irreversible or other serious, long-lasting adverse health effects or an impaired 24 ability to escape. 25 26AEGL-3 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 27 which it is predicted that the general population, including susceptible individuals, could 28 experience life-threatening health effects or death. 29 30 Airborne concentrations below the AEGL-1 represent exposure levels that could produce 31 mild and progressively increasing but transient and nondisabling odor, taste, and sensory 32 irritation or certain asymptomatic, non-sensory effects. With increasing airborne concentrations 33 above each AEGL, there is a progressive increase in the likelihood of occurrence and the severity 34 of effects described for each corresponding AEGL. Although the AEGL values represent 35 threshold levels for the general public, including susceptible subpopulations, such as infants, 36 children, the elderly, persons with asthma, and those with other illnesses, it is recognized that 37 individuals, subject to unique or idiosyncratic responses, could experience the effects described 38 at concentrations below the corresponding AEGL. 39 HYDROGEN BROMIDE/HYDROGEN IODIDE NAC/Interim 2: 04/2010 Page 3 of 34 1 TABLE OF CONTENTS 2 PREFACE.....................................................................................................................................................2 3 LIST OF TABLES ........................................................................................................................................5 4 EXECUTIVE SUMMARY...........................................................................................................................6 5 1. INTRODUCTION................................................................................................................................8 6 2. HUMAN TOXICITY DATA ...............................................................................................................9 7 2.1. Acute Lethality.............................................................................................................................9 8 2.2. Nonlethal Toxicity .......................................................................................................................9 9 2.3. Neurotoxicity ............................................................................................................................. 10 10 2.4. Developmental/Reproductive Toxicity ......................................................................................10 11 2.5. Genotoxicity...............................................................................................................................10 12 2.6. Carcinogenicity..........................................................................................................................10 13 2.7. Summary....................................................................................................................................10 14 3. ANIMAL TOXICITY DATA ............................................................................................................ 11 15 3.1. Acute Lethality...........................................................................................................................11 16 3.1.1. Rats........................................................................................................................................ 11 17 3.1.2. Mice....................................................................................................................................... 13 18 3.2. Nonlethal Toxicity .....................................................................................................................13 19 3.3. Neurotoxicity ............................................................................................................................. 13 20 3.4. Developmental/Reproductive Toxicity ......................................................................................13 21 3.5. Genotoxicity...............................................................................................................................14 22 3.6. Chronic Toxicity/Carcinogenicity.............................................................................................. 14 23 3.7. Summary....................................................................................................................................14 24 4. SPECIAL CONSIDERATIONS ........................................................................................................ 14 25 4.1. Metabolism and Disposition ......................................................................................................14 26 4.2. Mechanism of Toxicity.............................................................................................................. 14 27 4.3. Structure-Activity Relationships ................................................................................................15 28 4.4. Other Relevant Information ....................................................................................................... 15 29 4.4.1. Species Variability................................................................................................................. 15 30 4.4.2. Susceptible Populations......................................................................................................... 16 31 4.4.3. Concentration-Exposure Duration Relationship ....................................................................16 32 4.4.4. Concurrent Exposure Issues .................................................................................................. 16 HYDROGEN BROMIDE/HYDROGEN IODIDE NAC/Interim 2: 04/2010 Page 4 of 34 1 5. DATA ANALYSIS FOR AEGL-1.....................................................................................................16 2 5.1. Summary of Human Data Relevant to AEGL-1......................................................................... 16 3 5.2. Summary of Animal Data Relevant to AEGL-1 ........................................................................ 16 4 5.3. Derivation of AEGL-1 ...............................................................................................................17 5 6. DATA ANALYSIS FOR AEGL-2.....................................................................................................18 6 6.1. Summary of Human Data Relevant to AEGL-2......................................................................... 18 7 6.2. Summary of Animal Data Relevant to AEGL-2 ........................................................................ 18 8 6.3. Derivation of AEGL-2 ...............................................................................................................18 9 7. DATA ANALYSIS FOR AEGL-3.....................................................................................................19 10 7.1. Summary of Human Data Relevant to AEGL-3......................................................................... 19 11 7.2. Summary of Animal Data Relevant to AEGL-3 ........................................................................ 19 12 7.3. Derivation of AEGL-3 ...............................................................................................................20 13 8. SUMMARY OF AEGLS ................................................................................................................... 20 14 8.1. AEGL Values and Toxicity Endpoints ......................................................................................20 15 8.2. Comparison with Other Standards and Guidelines ....................................................................21 16 8.3. Data Adequacy and Research Needs..........................................................................................22